Arcutis Biotherapeutics
ARQT
ARQT
187 hedge funds and large institutions have $1.2B invested in Arcutis Biotherapeutics in 2024 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 73 increasing their positions, 48 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
2% more capital invested
Capital invested by funds: $1.18B → $1.2B (+$20M)
0.62% more ownership
Funds ownership: 109.28% → 109.9% (+0.62%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Holders
187
Holding in Top 10
4
Calls
$5.83M
Puts
$989K
Top Buyers
| 1 | +$10.7M | |
| 2 | +$7.61M | |
| 3 | +$7.56M | |
| 4 |
Goldman Sachs
New York
|
+$7.28M |
| 5 |
D.E. Shaw & Co
New York
|
+$6.86M |
Top Sellers
| 1 | -$10.1M | |
| 2 | -$9.59M | |
| 3 | -$7.34M | |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$5.37M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$4.55M |